Journal article
Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative
PloS one, Vol.13(12), pp.e0207509-e0207509
2018
DOI: 10.1371/journal.pone.0207509
PMCID: PMC6279038
PMID: 30513095
Abstract
Carpal tunnel syndrome (CTS) is a common and debilitating condition that commonly affects postmenopausal women.
To determine the effect of menopausal hormone therapy (HT) in healthy postmenopausal women on CTS risk.
We conducted a secondary analysis of the Women's Health Initiative's (WHI) HT trials linked to Medicare claims data. Separate intention-to-treat analyses were performed for the two trials; the conjugated equine estrogens alone (CEE alone) and the trial of CEE plus medroxyprogesterone acetate (MPA) trial. (ClinicalTrials.gov, NCT number): NCT00000611.
Two randomized, double-blind, placebo-controlled trials conducted at 40 US clinical centers.
The sample size included in the analysis was 16,053 community-dwelling women aged ≥65 years at study entry or those who later aged into Medicare eligibility, and who were enrolled in Medicare (including Part A and/or Part B coverage).
Women with hysterectomy were randomized to 0.625 mg/d of conjugated equine estrogens (CEE) or placebo (n = 8376). Women without hysterectomy were randomized to estrogen plus progestin (E+P), given as CEE plus 2.5 mg/d of medroxyprogesterone acetate (n = 14203).
The primary outcome was incident CTS and the secondary outcome was therapeutic CTS procedure occurring during the intervention phases of the trials.
A total of 16,053 women were randomized in both trials. During mean follow up of 4.5 ± 2.8 years in the CEE trial (n = 6,833), there were 203 incident CTS cases in the intervention and 262 incident CTS cases in the placebo group (HR, 0.78; 95% CI, 0.65-0.94; P = 0.009). The CEE+MPA trial (n = 9,220) followed participants for a mean of 3.7 ± 2.3 years. There were 173 incident CTS cases in the intervention compared to 203 cases in the placebo group (HR, 0.80, 95% CI, 0.65-0.97; P = 0.027).
These findings suggest a protective effect of menopausal HT on the incidence of CTS among postmenopausal women. A potential therapeutic role for other forms of estrogen therapy in the management of CTS warrants future research.
Details
- Title: Subtitle
- Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative
- Creators
- Tala Al-Rousan - Harvard Global Health InstituteJeffrey A Sparks - Brigham and Women's HospitalMary Pettinger - Fred Hutch Cancer CenterRowan Chlebowski - City Of Hope National Medical CenterJoAnn E Manson - Brigham and Women's HospitalAndrew M Kauntiz - Florida CollegeRobert Wallace - University of Iowa
- Resource Type
- Journal article
- Publication Details
- PloS one, Vol.13(12), pp.e0207509-e0207509
- DOI
- 10.1371/journal.pone.0207509
- PMID
- 30513095
- PMCID
- PMC6279038
- NLM abbreviation
- PLoS One
- ISSN
- 1932-6203
- eISSN
- 1932-6203
- Grant note
- HHSN268201600018C / NHLBI NIH HHS L30 AR066953 / NIAMS NIH HHS T32 AI007384 / NIAID NIH HHS HHSN268201600003C / NHLBI NIH HHS HHSN268201600004C / NHLBI NIH HHS HHSN268201600002C / NHLBI NIH HHS HHSN268201600001C / NHLBI NIH HHS K23 AR069688 / NIAMS NIH HHS
- Language
- English
- Date published
- 2018
- Academic Unit
- Epidemiology; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984364416702771
Metrics
23 Record Views